Kabiven

Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, and Serine, the active ingredients in Kabiven, are an amino acid solution presented as a parenteral nutrition formulation for intravenous use. It supplies essential amino acids for patients who cannot receive enteral nutrition.

GNH USA supplies Kabiven as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, clinics, and procurement teams worldwide. The company emphasizes quality assurance, regulatory compliance and reliable cold‑chain logistics where required to meet the needs of global healthcare providers.

Kabiven is employed in parenteral nutrition to deliver essential amino acids for protein synthesis in patients with impaired oral or enteral intake. - Parenteral nutrition for patients requiring amino acid supplementation: supports nitrogen balance and protein synthesis in individuals unable to receive enteral feeding. - Critical care patients with increased metabolic demand: provides rapid amino acid delivery to meet catabolic stress and maintain lean body mass during intensive therapy. - Post‑operative patients unable to tolerate oral/enteral intake: maintains nutritional status and promotes wound healing during the recovery period.

Kabiven may be associated with infusion‑related and metabolic adverse reactions.

Common Side Effects: - Hyperglycemia: elevated blood glucose levels, especially in diabetic patients. - Electrolyte imbalance: changes in serum potassium, sodium or calcium. - Phlebitis at infusion site: local vein inflammation or pain. - Hypotension: transient drop in blood pressure during rapid infusion. - Fever: mild temperature rise without infection.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate treatment. - Metabolic acidosis: significant drop in blood pH due to acid accumulation. - Renal dysfunction: impaired kidney function in susceptible individuals.

When using Kabiven, clinicians should observe several precautionary measures to ensure patient safety. - Renal impairment: monitor serum creatinine and adjust infusion rate. - Hepatic dysfunction: assess liver function tests before and during therapy. - Electrolyte monitoring: check serum electrolytes regularly and correct abnormalities. - Hyperglycemia risk: monitor blood glucose in diabetic or pre‑diabetic patients. - Compatibility: verify compatibility with other intravenous solutions before mixing. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kabiven can interact with certain intravenous agents and systemic therapies.

Major Interactions (Avoid): - Concurrent high‑dose potassium solutions: may cause severe hyperkalemia. - Calcium‑containing infusions (e.g., calcium chloride): can precipitate with amino acids. - Renal replacement therapy: may alter amino acid clearance and require dose adjustment.

Moderate Interactions (Monitor Closely): - Loop diuretics: may affect electrolyte balance during therapy. - Insulin therapy: may require closer glucose monitoring due to amino‑acid‑induced gluconeogenesis. - Anticoagulants (e.g., heparin): may increase risk of bleeding if infusion rates are rapid.